Back

What we still need to learn from sodium–glucose co-transporter 2 inhibitors to predict the future.

26 May 2019 (13:25 - 13:35)
Organised by:
Congress Presentation Part of: Sodium–glucose co-transporter 2 inhibition and the heart: lessons from cardiovascular outcomes trials in Type 2 diabetes (EBAC Accredited) Diabetes and the Heart HFA Premium Access Heart Failure 2019

About the speaker

Photo
Professor Martin Cowie

London (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
Welcome and introductions - Sodium–glucose co-transporter 2 inhibition and the heart: lessons from cardiovascular outcomes trials in Type 2 diabetes.
Professor A. Mebazaa (Paris, FR)
Presentation thumbnail
What have cardiovascular outcomes trials taught us about cardiovascular risk management?
Professor M. Pfeffer (Boston, US)
Presentation thumbnail
Emerging knowledge on cardiorenal protection.
Professor S. Verma (Toronto, CA)
Presentation thumbnail
From classroom to clinic: sodium–glucose co-transporter 2 inhibitor evidence in practice.
Professor S. Verma (Toronto, CA) Professor M. Cowie (London, GB) Doctor S. Wiviott (Boston, US) Professor A. Mebazaa (Paris, FR)
Presentation thumbnail
Q&A - Sodium–glucose co-transporter 2 inhibition and the heart: lessons from cardiovascular outcomes trials in Type 2 diabetes.
Professor M. Cowie (London, GB) Professor S. Verma (Toronto, CA) Professor M. Pfeffer (Boston, US) Professor A. Mebazaa (Paris, FR)

Access the full session

Session thumbnail
Sodium–glucose co-transporter 2 inhibition and the heart: lessons from cardiovascular outcomes trials in Type 2 diabetes (EBAC Accredited)

The Event

Event poster

Heart Failure 2019

26 May 2019 13:25 CET
You may be interested in
thumbnail
Congress Presentation
Temporal trends and clinical predictors of GLP-1 receptor agonist and SGLT2 inhibitor use after myocardial infarction among patients with type 2 diabetes
29 August 2026
thumbnail
Congress Presentation
The prognostic value of sodium-glucose co-transporter-2 inhibitors therapy among patients with cancer and diabetes mellitus, treated with immune checkpoint inhibitors
21 May 2023
thumbnail
Congress Presentation
Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish Heart Failure Registry
23 May 2022
thumbnail
Congress Presentation
3 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources